Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Bringing leukemia out of hiding

19.04.2010
Two new strategies target a deadly cancer that eludes conventional chemotherapy

Acute myeloid leukemia (AML) is the most common form of adult leukemia, and with an estimated five-year survival rate of 20%, the long-term prognosis for many patients is relatively grim.

“Current treatments for AML can initially reduce the number of AML cells to undetectable levels, a state referred to as ‘complete remission’,” says Fumihiko Ishikawa of the RIKEN Research Center for Allergy and Immunology in Yokohama. “Unfortunately, in a substantial proportion of these patients, AML eventually comes back—and many that relapse succumb to the disease.” The need for an improved arsenal to fight AML has guided much of Ishikawa’s work, and two recently published articles from his team present promising strategies for tackling this dreaded cancer.

AML originates in bone marrow, and relapse is initiated from small pockets of chemotherapy-resistant ‘leukemia stem cells’ (LSCs) within the marrow, which can be identified by their distinctive profile of cell-surface markers. In an effort to identify other features of LSCs that might offer useful therapeutic targets, Ishikawa, Yoriko Saito and team performed a thorough comparative analysis between LSCs and normal blood stem cells to identify genes with functional characteristics pertinent to cancerous growth whose expression is specifically elevated in LSCs1.

... more about:
»AML »Allergy »LSCs »RIKEN »stem cells

Their analysis revealed two candidate cell-surface proteins, CD25 and CD32; both of these are commonly overexpressed in chemotherapy-resistant LSCs, but can also be therapeutically targeted without negatively affecting blood cell development from healthy hematopoietic stem cells, making them potentially promising targets for thwarting relapse.

In parallel, Ishikawa and colleagues have also explored methods for boosting the efficiency of chemotherapy. Standard AML drugs such as cytosine arabinoside (Ara-C) work by targeting actively dividing cells, and LSCs are believed to elude chemotherapy by entering a quiescent, non-dividing state. The researchers hypothesized that LSCs could be made more vulnerable to Ara-C via simultaneous treatment with cytokines—naturally-occurring cell signaling molecules—that stimulate them into active division2. In fact, this two-pronged treatment led to a ten-fold increase in survival rate relative to chemotherapy alone for mice that had been transplanted with human LSCs.

Previous studies have suggested that despite some risk of toxicity, cytokine treatment is relatively safe for patients, and Ishikawa’s team is actively investigating the practicality and safety of interventions based on both of their recent discoveries. “We have been putting our best effort into the translation of these findings into medicine,” he says. “At the same time, we are continuing to try to identify unknown aspects of human AML and AML stem cells.”

The corresponding author for this highlight is based at the Research Unit for Human Disease Model, RIKEN Research Center for Allergy and Immunology

1. Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y. et al. Identification of therapeutic targets for quiescent chemotherapy-resistant human leukemia stem cells. Science Translational Medicine 2, 17ra9 (2010).

2. Saito, Y., Uchida, N., Tanaka, S., Suzuki, N., Tomizawa-Murasawa, M., Sone, A., Najima, Y., Takagi, S., Aoki, Y., Wake, A. et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nature Biotechnology 28, 275–280 (2010).

gro-pr | Research asia research news
Further information:
http://www.riken.jp
http://www.researchsea.com
http://www.rikenresearch.riken.jp/eng/research/6234

Further reports about: AML Allergy LSCs RIKEN stem cells

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>